

392

European Medicines Agency
Domenico Scarlattilaan 6,
1083 HS Amsterdam

Radboud university medical center
Radboudumc Technology Center Clinical Studies

P.O. Box 9101, 6500 HB Nijmegen
The Netherlands
Internal postal code 392
Philips van Leydenlaan 15
Radboudumc entrance west, route 392
T +31 24 366 83 33

Manager Policy, Quality and Support
mrs. J.A.H. Droste, PhD
rtclinicalstudies@radboudumc.nl
www.radboudumc.nl

Date	Our reference	Page
20 June 2022	AN/GR	1 of 1
Your reference	Contact	
	RTC Clinical Studies	

Dutch Chamber of Commerce
trade register 80262783

Subject
Results posting of 2007-001089-33

Dear EMA,

On behalf of the Prof. dr. G.A.P.J.M. Rongen as the 2nd Sponsor of this study, I hereby confirm that the screening and inclusion of subjects in the following clinical trial protocol: "Infusion of a single dose of erythropoietin to Prevent Injury in an Ischemia Reperfusion forearm model - A randomised cross-over study to evaluate if infusion of a single dose of EPO protects against ischemia-reperfusion injury in man" with EudraCT number **2007-001089-33**, had never started.

The reason for this is that the study product, Annexin A5, did not come available.

We hope this information is satisfactory to finalize results posting.

With kind regards,

Arjan Nooteboom,
Research Consultant at RTC Clinical Studies
Radboudumc
arjan.nooteboom@raboudumc.nl

cc Prof.dr. G.A.P.J.M Rongen